A study published in the ASAIO Journal examined the outcomes of 47 patients who had received SynCardia Total Artificial Heart support for greater than one year. Among them, 72% received donor heart transplants and one (2%) was awaiting a donor heart.
Giuseppe Gargiulo (Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy) and others report in Circulation: Cardiovascular Interventions that patients with moderate-to-severe chronic kidney disease have significantly worse outcomes after transcatheter aortic valve implantation (TAVI) than have patients with mild disease.
Corindus Vascular Robotics has announced that a study submitted by a physician user of the company’s CorPath System will be presented at the Cardiovascular Research Technologies (CRT) conference on Monday, 23 February, 2015, in Washington, DC, USA. The study, led by Paul T Campbell, Carolinas Medical Center Northeast, explores the stent savings made possible when robotic percutaneous coronary intervention (PCI) is leveraged for the measurement of anatomy in place of the conventional, manual methods of measurement.
Bellerophon Therapeutics has strengthened its drug and device development capabilities with the recent additions of Deborah A Quinn, vice president and medical lead for the INOpulse programmes and Martin Dekker as vice president of device engineering. Both are newly-created positions on the Bellerophon executive team.
Medtronic has announced CE mark for the 26mm and 29mm sizes of the CoreValve Evolut R System, a self-expanding valve that advances performance and deliverability during transcatheter aortic valve implantation (TAVI), while providing the option to recapture and reposition the valve during procedures.
A minimally invasive procedure to repair severe mitral valve regurgitation by clipping together the valve’s leaflets can improve function and quality of life and reduce the risk of hospitalisation, research shows. Approximately a third of patients who have the procedure need more than one clip to correct the problem, suggest data being presented at the 27th annual International Symposium on Endovascular Therapy (ISET).
Three imaging studies that were presented as late-breaking trials at the 2014 Transcatheter Cardiovascular Therapy (TCT) meeting (13–17 September, Washington, DC, USA) provided, respectively, the first randomised controlled data for routine use of optical coherence tomography (OCT) guidance during stent placement in patients with ST-segment elevation myocardial infarction (STEMI), the role of intravascular ultrasound (IVUS) in patients with chronic total occlusions, and the use of fractional flow reserve (FFR) for guiding provisional stenting in patients with bifurcation lesions.
Biotronik has completed patient enrolment for the BIOFLOW-IV study. The study is intended to support Japanese government approval of the Orsiro hybrid drug-eluting stent, which received CE mark in 2011.
Micell has announced the commercial availability of the MiStent sirolimus-eluting absorbable polymer coronary stent system in Europe. Stentys, Micell’s distribution partner in Paris, plans a controlled launch in Western Europe followed by a full commercial launch for the second half of 2015 in selected countries within Europe, Middle East, South-East Asia and Latin America.
MicroPort has received CE mark approval from the European Notified Body for its Firehawk rapamycin target eluting coronary stent system.
FEops, has announced the closing of a €1.3m series A financing round, led by Capricorn Venture Partners and PMV. The funding will be used to support the launch of FEops’ first product, TAVIguide, in key markets in Europe and the USA.
Transcatheter Technologies is further expanding its product platform to include an endoVascular aortic repair (EVAR) device: Tumbao
On-X Life Technologies will launch its Chord-X mitral valve chordal repair system at the Society of Thoracic Surgeons (STS) Annual Meeting (24–27 January, 2015, San Diego, USA).
More than 10% of patients treated with aspirin therapy for primary cardiovascular disease prevention were likely inappropriately prescribed medication, according to a new study in the Journal of the American College of Cardiology that examined practice variations in aspirin therapy.
Sorin has completed US enrolment of the Perceval Investigation Device Exemption (IDE) trial. The trial enrolment was completed on schedule with the implantation of 300 patients.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos